-transparent.png){kind=logo}
Using probes to manipulate hypothalamic neuronal histamine, we report here that changes in neuronal histamine modulate physiological feeding behavior in rats. Infusion of alpha-fluoromethylhistidine (FMH), a "suicide" inhibitor of histidine decarboxylase (HDC), into the third cerebroventricle induced feeding in the early light phase when the histamine synthesis was most accelerated. FMH at an optimum 2.24 mumol dose elicited feeding in 100% of rats. Treatment of FMH specifically and selectively decreased concentration of histamine without affecting concentrations of catecholamines in the hypothalamus. Immediately before the dark phase, when the histamine synthesis was normally lower, FMH infusion did not affect feeding-related parameters such as meal size, meal duration or latency to eat. Conversely, thioperamide, which facilitates both synthesis and release of neuronal histamine by blocking presynaptic autoinhibitory H3 receptors, significantly decreased food intake after infusion of a 100-nmol dose into the third cerebroventricle. The effect of thioperamide was abolished with i.p. injection of 26 mumol/kg chlorpheniramine, an H1antagonist. FMH at 224 nmol was microinfused bilaterally into the feeding-related nuclei in the hypothalamus. The ventromedial nucleus (VMH) and the paraventricular nucleus (PVN), but not the lateral hypothalamus, the dorsomedial hypothalamus or the preoptic anterior hypothalamus were identified as the active sites for the modulation. Neuronal histamine may convey suppressive signals of food intake through H1 receptors in the VMH and the PVN with diurnal fluctuation.
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
January 2002,
Experimental biology and medicine (Maywood, N.J.),
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
December 1994,
Neuropharmacology,
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
August 2007,
Mini reviews in medicinal chemistry,
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
August 1982,
Life sciences,
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
August 1994,
The American journal of physiology,
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
February 1999,
Biological psychiatry,
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
January 1957,
Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
January 2009,
Brain research,
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
December 2020,
Nature communications,
K Ookuma, and
T Sakata, and
K Fukagawa, and
H Yoshimatsu, and
M Kurokawa, and
H Machidori, and
K Fujimoto
February 1991,
Naunyn-Schmiedeberg's archives of pharmacology,
